Cargando…
Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses
Vaccines against a variety of infectious diseases have been developed and tested. Although there have been some notable successes, most are less than optimal or have failed outright. There has been discussion about whether either B cells or dendritic cells (DCs) could be useful for the development o...
Autores principales: | Fujii, Shin-ichiro, Yamasaki, Satoru, Sato, Yusuke, Shimizu, Kanako |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995044/ https://www.ncbi.nlm.nih.gov/pubmed/29915600 http://dx.doi.org/10.3389/fimmu.2018.01267 |
Ejemplares similares
-
Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells
por: Fujii, Shin-ichiro, et al.
Publicado: (2017) -
Eomes transcription factor is required for the development and differentiation of invariant NKT cells
por: Shimizu, Kanako, et al.
Publicado: (2019) -
Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells
por: Shimizu, Kanako, et al.
Publicado: (2015) -
NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
por: Fujii, Shin-ichiro, et al.
Publicado: (2013) -
NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
por: Shimizu, Kanako, et al.
Publicado: (2020)